Key Points
- CEO Joseph Burnett sold 20,000 shares on Jan. 9 at an average price of $16.12 for $322,400, reducing his stake by 63.36% to 11,565 shares per an SEC filing.
- ClearPoint shares are down about 7.5% and the company reported weak results last quarter — EPS -$0.21 (miss) and revenue $5.36M vs. $9.60M est. — with large negative margins and ROE.
- The outlook is mixed: the stock has an average rating of "Moderate Buy" (three Buys, one Sell) while institutional investors own roughly 30.08% and several funds made modest position changes.
ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) CEO Joseph Burnett sold 20,000 shares of the stock in a transaction on Friday, January 9th. The shares were sold at an average price of $16.12, for a total value of $322,400.00. Following the completion of the transaction, the chief executive officer owned 11,565 shares of the company's stock, valued at $186,427.80. The trade was a 63.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
ClearPoint Neuro Trading Down 7.5%
Shares of CLPT stock opened at $14.47 on Wednesday. The firm has a market capitalization of $411.24 million, a P/E ratio of -17.23 and a beta of 0.91. ClearPoint Neuro, Inc. has a twelve month low of $9.76 and a twelve month high of $30.10. The company has a quick ratio of 5.56, a current ratio of 6.37 and a debt-to-equity ratio of 1.84. The stock's fifty day simple moving average is $14.46 and its 200 day simple moving average is $15.05.
ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). ClearPoint Neuro had a negative net margin of 67.40% and a negative return on equity of 114.28%. The firm had revenue of $5.36 million during the quarter, compared to the consensus estimate of $9.60 million. As a group, sell-side analysts predict that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in CLPT. Parsons Capital Management Inc. RI lifted its position in shares of ClearPoint Neuro by 0.7% in the 2nd quarter. Parsons Capital Management Inc. RI now owns 143,486 shares of the company's stock worth $1,713,000 after purchasing an additional 950 shares during the period. MGO One Seven LLC raised its stake in ClearPoint Neuro by 6.0% during the third quarter. MGO One Seven LLC now owns 19,026 shares of the company's stock worth $415,000 after buying an additional 1,077 shares during the last quarter. Financial Management Professionals Inc. acquired a new position in ClearPoint Neuro in the third quarter valued at $28,000. Pekin Hardy Strauss Inc. boosted its position in ClearPoint Neuro by 3.6% during the second quarter. Pekin Hardy Strauss Inc. now owns 50,575 shares of the company's stock valued at $604,000 after acquiring an additional 1,750 shares during the last quarter. Finally, Allworth Financial LP boosted its position in ClearPoint Neuro by 3,076.9% during the second quarter. Allworth Financial LP now owns 2,065 shares of the company's stock valued at $25,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors own 30.08% of the company's stock.
Analyst Ratings Changes
A number of research firms have weighed in on CLPT. Wall Street Zen lowered shares of ClearPoint Neuro from a "hold" rating to a "sell" rating in a report on Saturday, November 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of ClearPoint Neuro in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $19.67.
Read Our Latest Report on ClearPoint Neuro
About ClearPoint Neuro
(
Get Free Report)
ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company's flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.
The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
